18.77

0.66% 0.135

Teva Pharmaceutical Industries Ltd Adr (TEVA)

Overview News Price History Option Chain Financials Why TEVA Down? Discussions Forecast Stock Split Dividend History

Teva Pharmaceutical Industries Ltd Adr stock is traded at $18.77, with a volume of 2.33M. It is up +0.66% in the last 24 hours and up +7.27% over the past month. Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Previous Close:

$18.64

Open:

$18.64

24h Volume:

2.33M

Relative Volume:

0.38

Market Cap:

$21.16B

Revenue:

$16.29B

Net Income/Loss:

$-476.00M

P/E Ratio:

-9.3875

EPS:

-2

Net Cash Flow:

$679.00M

1W Performance:

+1.80%

1M Performance:

+7.27%

6M Performance:

+34.21%

1Y Performance:

+108.70%

1-Day Range:

$18.48

$18.78

1-Week Range:

$18.20

$18.80

52-Week Range:

$8.545

$19.08

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile

Name

Teva Pharmaceutical Industries Ltd Adr

Sector

Healthcare (1181)

Industry

Drug Manufacturers - Specialty & Generic (88)

Phone

972 (3) 914-8213

Address

TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV

Employee

37,851

Twitter

@TevaUSA

Next Earnings Date

2024-11-06

Latest SEC Filings

TEVA's Discussions on Twitter

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-10-24	Upgrade	Argus	Hold → Buy
Mar-08-24	Upgrade	JP Morgan	Underweight → Neutral
Feb-12-24	Upgrade	Piper Sandler	Neutral → Overweight
Jan-23-24	Upgrade	Jefferies	Hold → Buy
Jan-03-24	Upgrade	Piper Sandler	Underweight → Neutral
Dec-18-23	Initiated	HSBC Securities	Buy
Nov-27-23	Upgrade	UBS	Neutral → Buy
Jul-06-23	Upgrade	UBS	Sell → Neutral
May-25-23	Initiated	Morgan Stanley	Equal-Weight
May-18-23	Upgrade	Evercore ISI	In-line → Outperform
Jan-19-23	Downgrade	Jefferies	Buy → Hold
Nov-14-22	Downgrade	JP Morgan	Neutral → Underweight
Nov-04-22	Downgrade	UBS	Neutral → Sell
Oct-21-22	Resumed	Jefferies	Buy
Aug-05-22	Upgrade	BofA Securities	Neutral → Buy
Jun-14-22	Resumed	UBS	Neutral
May-17-22	Upgrade	BofA Securities	Underperform → Neutral
May-04-22	Downgrade	Piper Sandler	Neutral → Underweight
Apr-05-22	Upgrade	Barclays	Equal Weight → Overweight
Mar-25-22	Upgrade	Bernstein	Mkt Perform → Outperform
Jan-27-22	Downgrade	Argus	Buy → Hold
Oct-28-21	Downgrade	Raymond James	Outperform → Mkt Perform
May-04-21	Downgrade	UBS	Buy → Neutral
Apr-07-21	Resumed	RBC Capital Mkts	Sector Perform
Nov-25-20	Initiated	Oppenheimer	Perform
Aug-06-20	Upgrade	Barclays	Underweight → Equal Weight
Jul-27-20	Resumed	Goldman	Neutral
Jun-01-20	Upgrade	SunTrust	Hold → Buy
Apr-24-20	Resumed	Citigroup	Neutral
Apr-06-20	Upgrade	UBS	Neutral → Buy
Feb-24-20	Downgrade	Edward Jones	Hold → Sell
Nov-12-19	Upgrade	JP Morgan	Underweight → Neutral
Oct-17-19	Upgrade	Gabelli & Co	Hold → Buy
Aug-07-19	Downgrade	Evercore ISI	Outperform → In-line
Jul-19-19	Initiated	Wolfe Research	Peer Perform
Jul-15-19	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Jul-10-19	Resumed	Credit Suisse	Neutral
Jul-05-19	Upgrade	Argus	Hold → Buy
Jun-11-19	Initiated	Barclays	Underweight
Jun-03-19	Upgrade	Oppenheimer	Perform → Outperform
May-30-19	Downgrade	BofA/Merrill	Buy → Underperform
May-28-19	Downgrade	UBS	Buy → Neutral
Mar-20-19	Initiated	SunTrust	Hold
Mar-07-19	Resumed	UBS	Buy

View All

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Latest News

Nov 01, 2024

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone) - GlobeNewswire Inc.

Nov 01, 2024

Oct 30, 2024

Where Do Analysts See Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Heading? - Stocks Register

Oct 30, 2024

Oct 25, 2024

Biliary Tract Cancer Market Research Report 2024-2030 with Analyst Recommendations - GlobeNewswire Inc.

Oct 25, 2024

Oct 16, 2024